European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

Dubertret, Louis; Mrowietz, Ulrich; Ranki, Annamari; Kerkhof, P.C.M. van de; Chimenti, Sergio; Lotti, Torello; Schäfer, Gregor

doi:10.1111/j.1365-2133.2006.07405.x

Cited by 294 publications

(354 citation statements)

References 30 publications

Supporting

Mentioning

286

Contrasting

Unclassified

Order By: Relevance

“…In Germany, mean working days lost per year due to a PsO patient were 4.9 23. The socioeconomic burden of PsO increases with the severity of the disease 24. The rate of hospitalization of patients with severe PsO is twice that of patients with mild PsO 25.…”

Section: Introductionmentioning

confidence: 99%

Burden of chronic urticaria relative to psoriasis in five European countries

Balp

Khalil

Tian

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundQuantification of burden of chronic spontaneous urticaria (CSU) vs. psoriasis (PsO) is limited.ObjectiveTo evaluate the burden associated with CSU vs. PsO of all severities (overall PsO), mild and moderate/severe PsO.MethodsThis retrospective cross‐sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom. Outcomes included mental and physical component summary scores (MCS and PCS) calculated from the Short Form (SF)‐36v2 or SF‐12v2, SF‐6D health utility scores, self‐reported psychological complaints (anxiety, depression and sleep difficulties), work productivity and activity impairment, and self‐reported healthcare resource utilization. Bivariate and multivariate analyses for each outcome and comparative groups were conducted.ResultsThis analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health‐related quality of life (HRQoL) impairment vs. overall PsO (MCS: −2.4, PCS: −1.6, SF‐6D: −0.03; all P < 0.001). CU patients showed a higher risk of anxiety, depression and sleep difficulties [odds ratio (OR): 1.63, 1.34 and 1.56, respectively; all P < 0.01] and greater healthcare resource use vs. overall PsO. The overall activity impairment was significantly greater in CU patients than in overall PsO patients (P = 0.001), while the impact on work was not significantly different. The results vs. moderate/severe PsO group showed no significant differences on all outcomes.ConclusionBurden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO. Both diseases have a similar negative impact on work productivity.

show abstract

Section: Introductionmentioning

confidence: 99%

Burden of chronic urticaria relative to psoriasis in five European countries

Balp

Khalil

Tian

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Elle est constituée des kératinocytes basaux qui prolifèrent et se différencient en kératinocytes des couches supérieures, c'est-à-dire couche épineuse (stratum spinosum ou corps muqueux de Malpighi), couche granuleuse (stratum granulosum), et couche cornée (stratum corneum) en superficie. Les kératinocytes présents au niveau de la couche cornée (les [3]. Les lymphocytes T CD4 Th17 sont une variété de lymphocytes T sécrétant de l'interleukine (IL)-17A, de l'IL-17F, de l'IL-22, de l'IL-26, ainsi que du TNF (tumor necrosis factor)-α. Ils expriment le facteur de transcription ROR (retinoic acid-related orphan receptor)-γT et, à la membrane, le récepteur de chimiokine CCR6 (CC chemokine receptor 6) [4][5][6] (➜).…”

Section: Structure De La Peau Humaine Normaleunclassified

Immunopathologie du psoriasis

et al. 2016

View full text Add to dashboard Cite

> Le psoriasis est une maladie inflammatoire fréquente atteignant essentiellement la peau et parfois les articulations. Cette maladie chronique met rarement en jeu le pronostic vital mais altère significativement la qualité de vie. Le psoriasis est caractérisé, dans sa forme la plus fréquente, par des plaques érythémato-squameuses bien limitées associées à une prolifération exagérée des kératinocytes de l'épiderme, une inflammation et une hypervascularisation du derme superficiel. L'implication des lymphocytes T CD4 de type Th1 a été suspectée initialement. Plus récemment, la découverte du rôle prépondérant des lymphocytes T CD4 de type Th17 dans la maladie a conduit au développement d'inhibiteurs spécifiques de cette voie, tels que les anticorps anti-IL(interleukine)-23 (cytokine favorisant la différenciation des lymphocytes en Th17), anti-IL-17, anti-IL-17RA (récepteur de l'IL-17) et IL-22 (cytokine produite notamment par les lymphocytes Th17). < Structure de la peau humaine normaleLa peau humaine (Figure 1) est constituée de trois couches qui sont, de la profondeur à la superficie, l'hypoderme, le derme et l'épiderme. L'hypoderme est majoritairement constitué des adipocytes qui sont des cellules chargées de lipides. Le derme contient un tissu interstitiel formé de collagène, des vaisseaux sanguins, des annexes piloséba-cées et des cellules du système immunitaire. L'épiderme est constitué de kératinocytes organisés en quatre couches. La plus profonde, la couche basale (stratum basale), est au contact de la membrane basale qui sépare l'épiderme du derme superficiel. Elle est constituée des kératinocytes basaux qui prolifèrent et se différencient en kératinocytes des couches supérieures, c'est-à-dire couche épineuse (stratum spinosum ou corps muqueux de Malpighi), couche granuleuse (stratum granulosum), et couche cornée (stratum corneum) en superficie. Les kératinocytes présents au niveau de la couche cornée (les 1 Inserm U976, laboratoire oncodermatologie, immunologie et cellules souches cutanées, hôpi-tal Saint-Louis,

show abstract

“…Bu çal›flmadaki amac›m›z, P‹K‹'nin Türk psoriasis hastalar›nda kullan›lmas› için dilimizde geçerlili¤ini ve güvenilirli¤ini sa¤lamak ve, hastalar›n sosyodemografik ve klinik özelliklerin yaflam kalitesi ile olan iliflkisini saptamakt›. [24][25][26][27][28][29][30][31][32] . Psoriasis ‹fllev Kayb› ‹ndeksi, hem klinik çal›flmalarda hem de psoriasis hastalar›nda uygulanan tedavilerin de¤erlendirilmesine yönelik çal›flmalarda s›kl›kla kullan›lm›flt›r 33 .…”

Section: Giriflunclassified

The Turkish Version of the Psoriasis Disability Index: A Validation and Reliability Study

Fisek¹,

Gökdemir²,

Köşlü³

et al. 2011

TURKDERM

View full text Add to dashboard Cite

ÖzetAmaç: Psoriasis vulgaris, hastalar›n yaflam kalitesini önemli ölçüde etkileyen kronik bir hastal›kt›r. Hastal›¤a özgü gelifltirilen ilk ölçek olan "Psoriasis ‹fllev Kayb› ‹ndeksi" (P‹K‹), pek çok dilde geçerlilik ve güvenilirli¤ini kan›tlam›fl ve klinik çal›flmalarda kullan›lm›flt›r. Bu çal›flmada amac›m›z, P‹K‹'ni Türkçeye çevirerek, dilimizde geçerlili¤ini ve güvenilirli¤ini araflt›rmakt›. Gereç ve Yöntem: Ölçek, uluslararas› çeviri basamaklar› izlenerek Türkçeye çevrildi. Hastalar›n Psoriasis alan fliddet indeksi (PAfi‹) skorlar›, demografik ve klinik bulgular› kaydedildi. Güvenilirlik analizi için "iç yap› tutarl›l›¤›" ve "test-tekrar test" metotlar› kullan›ld›. Ölçekteki her bir soru ve alt gruplar için Cronbach alfa katsay›s› ve madde-toplam puan korelasyonlar› hesapland›. Geçerlilik analizi için, "Dermatoloji Yaflam Kalite ölçe¤i"(DYKÖ) ile karfl›laflt›rma yöntemi kullan›ld›. Elde edilen P‹K‹ skorlar›, hastalar›n demografik bulgular› ve klinik özellikleri ile karfl›laflt›r›ld›. Bulgular: Çal›flmaya 161 psoriasis hastas› al›nd›. ‹çyap› tutarl›l›k ölçümünde tüm alt ölçeklerin Cronbach alfa katsay›s› 0,61-0,79 aras›nda de¤iflmekte olup, tüm anket için 0,88 olarak hesapland›. Test-tekrar test güvenilirli¤inde, her bir soru için korelasyon katsay›s› 0,366-0,775 aras›nda de¤iflmekte olup, toplam P‹K‹ skoru için korelasyon katsay›s› r=0,854 olarak hesapland› (p<0,001). Geçerlilik analizleri için, ortalama P‹K‹ ve DYKÖ skorlar› aras›ndaki iliflki araflt›r›ld› ve her iki ölçek aras›nda korelasyon katsay›s› r= 0,674 bulundu (p<0,05). Sonuç: Çal›flmam›z, yap›lan güvenilirlik ve geçerlilik ölçümleri sonucunda P‹K‹'nin Türk psoriasis hastalar› için uygun bir ölçek oldu¤unu göstermektedir. (Türkderm 2011; 45: 24-8) Anahtar Kelimeler: Dermatoloji yaflam kalite ölçe¤i, psoriasis, psoriasis ifllev kayb› indeksi, yaflam kalitesi, türkçe versiyon Summary Background and Design: Several instruments are available for assessing impairment and disability associated with psoriasis. The first psoriasis-specific quality of life questionnaire, Psoriasis Disability Index (PDI), has been translated to many different languages and used in studies all around the world. The aim of this study was to translate the PDI into Turkish and to validate the Turkish version of the PDI and its use for Turkish psoriasis patients, as well as to examine the specific contribution of demographic and clinical features to the PDI. Material and Method: The questionnaire was translated into Turkish by using appropriate translation steps. The socio-demographic data and the Psoriasis Area and Severity Index (PASI) scores of the patients were recorded. For reliability analysis, internal consistency and test-retest method were used. The Cronbach's alpha coefficient and item-total statistics were calculated for each question and subscales. For validation, the questionnaire was compared with the Dermatology Life Quality Index (DLQI). Results: A total of 161 psoriasis patients were included in the study. For internal consistency, Cronbach's alpha coefficient...

show abstract

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

Abstract: This is the largest survey of people with psoriasis in Europe and shows that psoriasis has a profound impact on quality of life.

Cited by 294 publications

References 30 publications

Burden of chronic urticaria relative to psoriasis in five European countries

Burden of chronic urticaria relative to psoriasis in five European countries

Immunopathologie du psoriasis

The Turkish Version of the Psoriasis Disability Index: A Validation and Reliability Study

Contact Info

Product

Resources

About